Friday, September 29, 2023


Biotechnology News Magazine

Generian Achieves First Milestones in Mitobridge Collaboration

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Generian Pharmaceuticals, Inc., a preclinical biopharmaceutical company discovering and developing first-in-class orally bioavailable small molecule therapeutics, announced today that it has achieved the first research milestones for two programs in development under its collaboration agreement with Mitobridge, Inc. (a wholly-owned subsidiary of Astellas Pharma Inc.).

The two programs that Generian is advancing are focused on the stabilization or degradation of two unrelated transcription factors. The milestone payments were generated based on the successful identification of hit compounds that impact the stability and activity of these two transcription factors. The small molecule hit series were identified through the use of a proprietary drug discovery platform and validated as target protein stabilizers or degraders in biologically relevant functional assays.

“We are extremely pleased with the rapid and remarkable progress made with our partners at Astellas on these two programs,” said Hank Safferstein, PhD, JD, Chief Executive Officer of Generian. “These hit series represent first-in-class compounds that directly bind to transcription factors for degradation or stabilization. We look forward to continuing our productive collaboration and leveraging our combined expertise and knowledge to develop and advance small molecule therapeutics for difficult to drug targets.”

“As a company focused on developing innovative treatments for patients around the world, we are extremely pleased that Generian achieved their first program milestones,” said David Barrett, Ph.D., Division Head and President of Mitobridge. “We continue to be very excited about, and value, our ongoing collaboration with them.”

In June 2022, Generian and Astellas entered into a collaboration and exclusive license agreement to identify novel small molecules that modulate target proteins through activation, stabilization or degradation as potential development candidates. Generian is eligible to receive additional milestone payments of approximately $180 million in addition to royalties on any global net sales.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine